Last updated: 2026-09-05 10:16:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
ResMed Inc. (RMD) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $228.29, with a market capitalisation of $33.06B and a P/E ratio of 21.62. Over the past 52 weeks, its price has ranged from $180.27 to $284.87. This page covers its latest market performance, valuation, price trends and company information.
$33.06B | |
$230.28 | |
$301.34 | |
$9.45 | |
$229.19 | |
613.14K | |
1.47M | |
21.62 | |
$284.87 | |
$180.27 | |
1.06% | |
-- |
ResMed Inc. (RMD) last closed at $229.19 as of 2026-09-04 23:31:00, unchanged from the previous close of $229.19.
During the latest regular trading session, RMD traded between $9.45 and $301.34, with a volume of 613.14K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, ResMed Inc. (RMD) moved from $235.76 to $228.29, representing a decline of 3.17% ($7.47).
The stock traded between $225.12 and $242.40 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.31 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45.9%
RMD is currently trading at $228.29, placing it 45.9% of the way from its 52-week low of $180.27 to its 52-week high of $284.87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 11370 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of ResMed Inc. (RMD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.